Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern Time to discuss its third quarter 2024 financial results.

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Check the time stamp on this data. Updated AI-Generated Signals for Ionis Pharmaceuticals Inc. (IONS) available here: IONS.

Avacta Therapeutics has entered a strategic collaboration with Tempus AI to advance the development of drugs in oncology.

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.

AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with ...

Wainzua had been previously approved for use by patients with ATTRv-PN in the United States, under the brand name Wainua.

AstraZeneca and Ionis' drug Wainzua (eplontersen) has been recommended for approval in the European Union for treating ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of ...

While success is far from guaranteed in bio-land, with this week’s raising, Percheron has the horsepower to have a decent ...

Ionis Pharmaceuticals (IONS) announced that Ionis’ and AstraZeneca’s (AZN) Wainzua has been recommended for approval by the ...

(Alliance News) - AstraZeneca PLC on Monday said its Wainzua treatment has been been recommended for EU approval to treat ...